Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.

Leishmania major, the agent of Oriental sore, is an obligate intracellular parasite of macrophages in mammalian hosts. Man's immune defense against this organism requires participation of specifically sensitized lymphocytes and activated macrophages. Recent studies, however, have demonstrated that as little as 1/120 concentration of normal human serum is highly cytotoxic for the amastigote form of L. major. Initiation of the lethal process occurs rapidly, requiring only 30 sec of parasite exposure to serum, and is mediated by antibody-independent activation of the alternate complement pathway. The molecular mechanism of cytotoxicity is not known, but may require participation of the membrane attack complex, C5b-9. We investigated this possibility by treating amastigotes with human sera genetically deficient in complement components C5, 6, 7, 8, or 9. We then measured viability of treated parasites by amastigote-promastigote conversion. Our results were quite unexpected: not only did C9-deficient serum kill organisms, but sera singly deficient in each of the preceding components C6 to C8 were also cytotoxic. The degree of cytotoxicity was related both to serum concentration and to the point in the complement cascade at which deficiency occurred. Sera lacking C6 or C7 were less cytotoxic than those deficient in C8, which were less toxic than those deficient in C9. Cytoxicity of deficient sera was abolished by heating serum to 56 degrees C for 30 min. These findings indicate that an incomplete membrane attack complex may mediate cytotoxicity for L. major amastigotes. Moreover, our results raise important questions regarding the mechanism by which the complex is assembled on the surface of a living, unicellular eukaryotic organism.

[1]  E. Podack,et al.  Membrane attack by complement. , 1984, Molecular immunology.

[2]  J. Tschopp Ultrastructure of the membrane attack complex of complement. Heterogeneity of the complex caused by different degree of C9 polymerization. , 1984, The Journal of biological chemistry.

[3]  M. Meltzer,et al.  Killing of Leishmania tropica amastigotes by factors in normal human serum. , 1984, Journal of immunology.

[4]  A. Ferrante,et al.  Alternative pathway activation of complement by African trypanosomes lacking a glycoprotein coat , 1983, Parasite immunology.

[5]  L. Reller,et al.  Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. , 1983, The New England journal of medicine.

[6]  B. H. Petersen,et al.  Two types of dysfunctional eighth component of complement (C8) molecules in C8 deficiency in man. Reconstitution of normal C8 from the mixture of two abnormal C8 molecules. , 1983, The Journal of clinical investigation.

[7]  M. Mayer,et al.  Size of the transmembrane channels produced by complement proteins C5b-8. , 1982, Journal of immunology.

[8]  M. Meltzer,et al.  Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages. , 1981, Journal of immunology.

[9]  A. Dalmasso,et al.  Lesions of different functional size produced by human and guinea pig complement in sheep red cell membranes. , 1981, Journal of Immunology.

[10]  M. Shin,et al.  Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell. , 1981, Journal of immunology.

[11]  T. Lint,et al.  Inherited deficiency of the ninth component of complement in man. , 1980, Journal of immunology.

[12]  F. Jensen,et al.  Disassembly of viral membranes by complement independent of channel formation. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Johnston,et al.  Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway. , 1978, The New England journal of medicine.

[14]  J. Ferluga,et al.  Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects. , 1978, Clinical and experimental immunology.

[15]  M. Mayer,et al.  On the mechanism of cytolysis by complement: evidence on insertion of C5b and C7 subunits of the C5b,6,7 complex into phospholipid bilayers of erythrocyte membranes. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Snyderman,et al.  Neutralization of Sensitized Virus by the Fourth Component of Complement , 1969, Science.